Sustaining Priority Research for Neglected Tropical Diseases Rob
Sustaining Priority Research for Neglected Tropical Diseases Rob Ridley Director, TDR Global Forum for Health Research Mumbai, September 12 to 16 2005 1
TDR 'twin' Mission • To undertake research, development and evaluation of new and improved tools and interventions to fight major tropical diseases • To strengthen research capabilities in countries where these diseases are endemic – enhanced stakeholdership / ownership of research Global Forum for Health Research Mumbai, September 12 to 16 2005 2
A vicious cycle Global Forum for Health Research Mumbai, September 12 to 16 2005 3
Many 'Neglected Diseases' Mortality Estimates for 2002 (World Health Report 2004) • Infectious and Parasitic diseases 10 904 (000) • HIV/AIDS • Diarrhoeal diseases • Tuberculosis • Malaria • Childhood diseases • STI (excluding HIV) • Meningitis • (Other) Tropical Diseases • Hepatitis B • Hepatitis C • Dengue • Japanese encephalitis • Intestinal nematode • Leprosy 2 777 1 798 1 566 1 272 1 124 180 173 129 103 54 19 14 12 6 ¨ ¨ ¨ ¨ Global Forum for Health Research Mumbai, September 12 to 16 2005 4
'Neglected' Diseases affect 'Neglected' Populations Global Forum for Health Research Mumbai, September 12 to 16 2005 5
Priority Setting Global Forum for Health Research Mumbai, September 12 to 16 2005 6
Tropical Disease Burden Poverty Str ate gy ? ? Poverty Control/ Elimination Of Tropical Research Diseases Global Forum for Health Mumbai, September 12 to 16 2005 reduction 7
Innovation to Impact Grand Challenges NIH, Trust, Research councils etc. Global Forum for Health Research Mumbai, September 12 to 16 2005 8
Need to sustain and increase basic science funding Global Forum for Health Research Mumbai, September 12 to 16 2005 9
Product Development Global Forum for Health Research Mumbai, September 12 to 16 2005 10
Examples of public private partnerships that have delivered new tools Global Forum for Health Research Mumbai, September 12 to 16 2005 11
Innovation to Impact – product development EDCTP MMV Microbicides DNDi GATB IAVI FIND MVI Global Forum for Health Research Mumbai, September 12 to 16 2005 12
Product Development Activities Need Sustaining • 8 new drugs anticipated by 2010 • Proposed fund of $200 M per year to complement PPP's Global Forum for Health Research Mumbai, September 12 to 16 2005 13
Much variation by disease (e. g. Gates) Global Forum for Health Research Mumbai, September 12 to 16 2005 14
Evaluation and Implementation Research Global Forum for Health Research Mumbai, September 12 to 16 2005 15
Examples of TDR – mediated evaluation and implementation research • Onchocerciasis – Ivermectin and Community Directed Treatment • Malaria – Home management of malaria strategies • Visceral Leishmaniasis – Tools in place for 'elimination' programmes A critical area for future funding given increase of tools in pipeline Global Forum for Health Research Mumbai, September 12 to 16 2005 16
Example in progress Visceral Leishmaniasis New tools stimulate India / Nepal / Bangladesh to sign Mo. U for elimination of VL by 2015 • • • Local ownership of research critical Recognition of significance of social, economic and behavioural research Research must be embedded in and owned by countries and integrated into health systems Inter-country coordination facilitated by WHO / SEARO / TDR Requires a co-ordinated approach by partners for maximal impact Global Forum for Health Research Mumbai, September 12 to 16 2005 17
Innovation to Impact Global Forum for Health Research Mumbai, September 12 to 16 2005 18
Innovation to Impact Global Forum for Health Research Mumbai, September 12 to 16 2005 19
Look beyond single issues Managing Interfaces Global Forum for Health Research Mumbai, September 12 to 16 2005 20
Challenges No. 1 • Maintained funding for basic science, continued innovation and PPP product development – Better balance for more neglected diseases – Better management of translation research • Enhanced Evaluation and Implementation Research for all diseases • Enhanced coordination and interaction between initiatives, funding agencies, governments and regional bodies – Role for international agencies Global Forum for Health Research Mumbai, September 12 to 16 2005 21
Look beyond single issues Cross-cutting issues Global Forum for Health Research Mumbai, September 12 to 16 2005 22
Challenges No. 2 • Need capacity building coupled to capacity utilisation • Need to enhance country participation, 'stakeholdership' and ownership of research • Need to 'embed' the output of research activities within the institutions of developing countries • Need to enhance capabilities of developing countries to engage in 'innovation' as well as implementation Global Forum for Health Research Mumbai, September 12 to 16 2005 23
Use-inspired Research Global Forum for Health Research Mumbai, September 12 to 16 2005 24
- Slides: 24